Lv51
1082 积分 2022-10-10 加入
N-Linked Glycans (N-Glycans)
7天前
已完结
MYC inhibition by OMO-103 induces immune cell recruitment in preclinical models of NSCLC and modulates the cytokine and chemokine profiles of Phase I patients showing stable disease
1个月前
已完结
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
2个月前
已完结
Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology
2个月前
已完结
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective
2个月前
已完结
Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study
6个月前
已完结
Drug-Linkers in Antibody–Drug Conjugates: Perspective on Current Industry Practices
6个月前
已完结
Strategies for UF/DF-Based Impurity Removal in the Post-conjugation Purification of Antibody–Drug Conjugates
6个月前
已完结
Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates
6个月前
已完结
Deriving acceptable limits for non-mutagenic impurities in medicinal products – Durational adjustments
7个月前
已完结
皖公网安备34019202002308
